DJI46,923.59+0.78%
GDAXI23,564.01+0.50%
GSPC6,696.99+0.98%
HSI25,834.02+1.45%
IXIC22,366.29+1.18%
N22553,751.15-0.13%
AAPL252.29+0.87%
AMZN212.02+2.09%
CL94.12-4.65%
EURUSD1.1518+0.83%
GBPUSD1.3330+0.81%
GC5,015.40-0.91%
GOOG304.17+0.90%
JPM285.98+0.90%
META627.34+2.31%
MSFT399.04+0.88%
NVDA183.18+1.63%
TSLA396.04+1.24%
DJI46,923.59+0.78%
GDAXI23,564.01+0.50%
GSPC6,696.99+0.98%
HSI25,834.02+1.45%
IXIC22,366.29+1.18%
N22553,751.15-0.13%
AAPL252.29+0.87%
AMZN212.02+2.09%
CL94.12-4.65%
EURUSD1.1518+0.83%
GBPUSD1.3330+0.81%
GC5,015.40-0.91%
GOOG304.17+0.90%
JPM285.98+0.90%
META627.34+2.31%
MSFT399.04+0.88%
NVDA183.18+1.63%
TSLA396.04+1.24%
DJI46,923.59+0.78%
GDAXI23,564.01+0.50%
GSPC6,696.99+0.98%
HSI25,834.02+1.45%
IXIC22,366.29+1.18%
N22553,751.15-0.13%
AAPL252.29+0.87%
AMZN212.02+2.09%
CL94.12-4.65%
EURUSD1.1518+0.83%
GBPUSD1.3330+0.81%
GC5,015.40-0.91%
GOOG304.17+0.90%
JPM285.98+0.90%
META627.34+2.31%
MSFT399.04+0.88%
NVDA183.18+1.63%
TSLA396.04+1.24%
CYBERETIKAGLOBAL FINANCIAL INTELLIGENCE
LIVE
SWE Dagens Industri SV

Novartis läkemedel godkänns av FDA

Det schweiziska läkemedelsbolaget Novartis psoriasisläkemedel Cosentyx har fått godkännande av USA:s den amerikanska läkemedelsmyndigheten FDA för behandling av patienter från 12 år med måttlig till svår hidradenitis suppurativa.

Mar 13, 2026 &03181313202631; 19:18 UTC www.di.se
Read original on www.di.se ↗
↗
Positive for markets
Sentiment score: +65/100
Moderate impact Short-term (days)
WHAT THIS MEANS
Novartis received FDA approval for Cosentyx to treat moderate to severe hidradenitis suppurativa in patients aged 12 and above, expanding the drug's therapeutic applications and revenue potential in the dermatology market.
AI CONFIDENCE
85% Very high
SENTIMENT GAUGE
NEWS POWER SCORE
AFFECTED ASSETS
↑
NOVN.SW
NOVN.SWStock
Expected to rise
FDA approval expands Cosentyx market opportunity in hidradenitis suppurativa treatment, supporting revenue growth and market share expansion in dermatology segment
↑
Euro Stoxx 50
^STOXX50EIndex
Expected to rise
Positive catalyst for European pharmaceutical sector, particularly Swiss healthcare companies
PRICE HISTORY
Loading chart...
⚡ SUGGESTED ACTION
Consider long positions on Novartis as the FDA approval validates Cosentyx's efficacy in a new indication, potentially driving incremental revenue growth. Monitor for additional label expansions and competitive responses in the hidradenitis suppurativa treatment space.
KEY SIGNALS
FDA approval for new indicationMarket expansion for existing drugPediatric indication (12+ years)Rare disease treatment opportunityRevenue diversification
SECTORS INVOLVED
HealthcarePharmaceuticalsBiotechnology
Analysis generated on Mar 16, 2026 at 13:23 UTC
Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Dagens Industri. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

RELATED INTELLIGENCE

Novartis unveils new share buyback program
Seeking Alpha Mar 16, 10:38 Positive
Sandoz creates biosimilar unit to benefit from major patent cliff
Seeking Alpha Mar 10, 15:59 Positive
Middle East oil exports drop at least 60% as Strait of Hormuz stays mostly closed, data shows
BNN Bloomberg Mar 16, 21:13 Negative
Bell plans $1.7B AI data centre in Saskatchewan as demand for computing power surges
BNN Bloomberg Mar 16, 21:03 Positive
Urbana Corporation Intersects 4.2 g/t Au over 10 Metres and Begins Second Drill Program
BNN Bloomberg Mar 16, 20:59 Positive